LIVN has been the topic of a number of other reports. BTIG Research reiterated a hold rating on shares of LivaNova in a report on Thursday, May 2nd. Piper Jaffray Companies cut their target price on LivaNova from $120.00 to $90.00 and set an in-line rating on the stock in a report on Wednesday, May 1st. Needham & Company LLC restated a buy rating and set a $87.00 price objective on shares of LivaNova in a research note on Tuesday, May 28th. BidaskClub upgraded LivaNova from a sell rating to a hold rating in a research note on Friday, July 26th. Finally, Stifel Nicolaus restated a buy rating and set a $100.00 price objective on shares of LivaNova in a research note on Friday, April 5th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $107.20.
Shares of LivaNova stock traded down $1.12 on Thursday, reaching $78.99. 480,535 shares of the company’s stock were exchanged, compared to its average volume of 372,743. The firm has a market cap of $3.80 billion, a P/E ratio of 24.92, a P/E/G ratio of 3.31 and a beta of 0.56. LivaNova has a 52 week low of $64.80 and a 52 week high of $131.54. The business has a 50-day moving average price of $73.17. The company has a quick ratio of 0.61, a current ratio of 0.95 and a debt-to-equity ratio of 0.15.
In other news, CFO Thad Allen Huston sold 2,000 shares of the firm’s stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $75.00, for a total transaction of $150,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Damien Mcdonald sold 1,000 shares of the firm’s stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $73.58, for a total value of $73,580.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,300 shares of company stock worth $387,999. Company insiders own 0.41% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Swiss National Bank increased its position in shares of LivaNova by 2.1% during the 2nd quarter. Swiss National Bank now owns 90,619 shares of the company’s stock valued at $6,521,000 after purchasing an additional 1,900 shares during the last quarter. Comerica Bank increased its position in shares of LivaNova by 127.4% during the 2nd quarter. Comerica Bank now owns 72,378 shares of the company’s stock valued at $5,245,000 after purchasing an additional 40,554 shares during the last quarter. Envestnet Asset Management Inc. increased its position in shares of LivaNova by 4.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 10,669 shares of the company’s stock valued at $768,000 after purchasing an additional 495 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in shares of LivaNova by 2,237.1% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 271,100 shares of the company’s stock valued at $19,512,000 after purchasing an additional 259,500 shares during the last quarter. Finally, Wedge Capital Management L L P NC purchased a new stake in shares of LivaNova during the 2nd quarter valued at $11,937,000. 84.08% of the stock is owned by hedge funds and other institutional investors.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Further Reading: QQQ ETF
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.